普瑞巴林治疗带状疱疹后神经痛的临床疗效观察

目的 观察普瑞巴林治疗带状疱疹后神经痛的临床疗效和安全性.方法 将48例带状疱疹后神经痛患者随机分成治疗组（27例）和对照组（21例）.治疗组给予普瑞巴林75 ～ 150 mg,2次/d口服,对照组予吲哚美辛25 mg,2～4次/d口服,观察时间为4周.采用视觉模拟评分（VAS）评估治疗前及治疗后疼痛程度,同时观察不良反应.结果 经过4周的治疗,2组患者VAS评分均较治疗前降低,治疗组较对照组VAS评分降低更显著（P=0.03）;治疗组有效率为68％,对组照有效率为35％,2组间差异有统计学意义（P=0.02）;治疗期间未见严重不良反应,2组间不良反应发生率差异无统计学意义（P=0.65）.结论 普瑞巴林治疗带状疱疹后神经痛疗效好,安全性高.

Clinical efficacy of pregabalin on patients with post-herpetic neuralgia

Objective To explore the efficacy and safety of pregabalin on patients with post-herpetic neuralgia. Methods 48 patients with post-herpetic neuralgia were randomized divided into treatment group（ n = 27 ） and control group（ n = 21 ）. The treatment group was given with pregabalin at the daily dosage from 150 to 300 mg according to pa- tients＇ response and tolerability. The control group was treated with indomethacin 25 mg 2 - 4 times per day. The visual analogue scale （VAS） for pain severity was measured before and 4 weeks after therapy ,and adverse effects were recorded as well. Results The VAS score of both group decreased after 4 weeks treatment with pregabalin or indomethacin,while pregabalin group decreased more significantly than indomethacin group（ P = 0.03 ）. The overall clinical efficacy rate was 68.0% in pregabalin group and 35.0% in indomethacin group（P = 0.02）. Severe adverse reactions did not oceur in our study,and there was no statistical difference in adverse rate between the two groups （ P = 0.65 ）. Conclusion Pregabalin was effective and safe for treating post-herpetic neuralgia.